View More Recent Stories

Jan 28, 2015 07:57AM Roth Remains Positive on Ligand (LGND) Following Kyprolis Q4 Sales Data, sNDA Filing (AMGN)
Jan 21, 2015 02:30PM Roth Affirms Curis (CRIS) at 'Buy' Following Aurigene Deal; Cuts PT to $6 on Dilution
Dec 26, 2014 02:43PM Roth Positive on Spectrum Pharma (SPPI) Following CE-Melphalan NDA Filing (LGND)
Dec 19, 2014 02:29PM Roth Comments on Ligand Pharma (LGND) Following EU Marketing Authorization of Duavive
Nov 11, 2014 07:50AM Sage (SAGE) SRSE Data is Positive for Ligand Pharma (LGND) - Roth
Oct 27, 2014 01:57PM Roth Capital 'Impressed' with Ligand's (LGND) Q3 Results; Affirms at 'Buy'
Oct 24, 2014 11:15AM Ligand's (LGND) Duavee Will be Significant N-T Revenue Driver; CHMP Opinion is Encouraging - Roth
Oct 23, 2014 08:45AM Roth Capital Lifts PT on Ligand (LGND) 32% Ahead of Q3 Results
Oct 22, 2014 08:40AM Roth Affirms Ligand (LGND) at 'Buy' Following Strong Promacta Sales in Q3
Sep 9, 2014 03:33PM Roth Keeps Ligand (LGND) at 'Buy' Following New Captisol-Based Tech Launch
Aug 28, 2014 11:11AM Interferon Therapy for HCV Still Expected Strong Amid Daklinza Approval - Roth (LGND) (BMY)
Aug 27, 2014 09:26AM Roth Comments on Ligand (LGND) Following Approval of Promact sNDA (GSK)
Aug 14, 2014 10:57AM Roth Remains Positive on Ligand Pharma (LNGD) Following New Licensing Agreement with Avion Pharma
Aug 4, 2014 02:24PM Roth Still Positive on Ligand (LGND) Following Q2 Results, ASPIRE Phase 3 Update (AMGN)
Jul 23, 2014 08:57AM Ligand (LGND) Pressure on GSK's Promacta Data is Overreaction - Roth Capital
Jul 22, 2014 10:07AM Roth Capital Comments on Ligand (LGND) Following SAGE-547 Update
Jul 18, 2014 07:54AM Roth Capital Sees Prelim. Q2 Revenue Numbers from Ligand (LGND) as Just the Beginning of More Success to Come
Jun 25, 2014 03:42PM Roth Capital Keeps LIgand Pharma (LGND) at Buy; Glaxo Initiates Promacta Phase III
Jun 24, 2014 09:34AM Roth 'Encouraged' by TG Therapeutics (TGTX), Ligand (LGND) Deal; Issues Commentary
Jun 23, 2014 12:04PM Streetinsider.com's Hot Lunchtime Reads 06/23: (MSFT) (LGND) (RSH) (YELP)
Jun 23, 2014 11:28AM Roth Capital Comments on New SERM Lasofoxifene Phase 1 Data
Jun 17, 2014 08:54AM UPDATE: Short-Seller Article on Ligand (LGND) is Silly, Underlying Strength Remains - Roth Capital
Jun 16, 2014 10:28AM LGD-6972 Could Drive Partnership; Roth Keeps Ligand Pharma (LGND) at 'Buy'
Jun 13, 2014 11:20AM New Promacta Data Should Support Approval for cITP; Roth has Ligand (LGND) at 'Buy'
May 23, 2014 07:26AM Roth 'Encouraged' by Ligand/Viking Transaction; Maintains at 'Buy' (LGND)
May 7, 2014 11:49AM Roth Affirms Ligand Pharma (LGND) at 'Buy'; Captisol, Promacta Lead Strong Q1 Results
Apr 30, 2014 10:00AM Roth Affirms Ligand (LGND) at Buy; FDA Grants Promacta/Revolade Priority Review
Mar 18, 2014 02:50PM Roth Still Bullish on Ligand Pharma (LGND) Following NOXAFIL Approval (MRK)
Feb 28, 2014 12:19PM Roth Still Positive on Ligand (LGND) Following Promacta sNDA Submission
Feb 12, 2014 07:23AM Roth Capital Lifts PT on Ligand (LGND) to $92; Still Sees Plenty of Positive Catalysts Ahead
Feb 3, 2014 09:55AM Roth Keeps Ligand (LGND) at Buy; BD Indication for Promacta is Pleasant Surprise
Jun 28, 2012 07:15AM Roth Capital Starts Ligand Pharma (LGND) at Buy
View More Recent Stories